Literature DB >> 25982097

The exaggerated inflammatory response in Behçet's syndrome: identification of dysfunctional post-transcriptional regulation of the IFN-γ/CXCL10 IP-10 pathway.

N Ambrose1, E Khan1, R Ravindran1, L Lightstone2, S Abraham2, M Botto2, M Johns1, D O Haskard1.   

Abstract

The mechanisms underlying the exaggerated inflammatory response in Behçet's syndrome (BS) remain poorly understood. We investigated the response of CD14(+) blood monocytes to interferon (IFN)-γ, focusing on the chemokine CXCL10. Chemokine synthesis and release were analysed at a protein and mRNA level following stimulation with IFN-γ. Findings in BS patients were compared with 25 healthy controls (HC), 15 rheumatoid arthritis (RA) and 15 systemic lupus erythematosus (SLE) disease control patients. BS monocytes produced significantly more CXCL10 protein than HC monocytes from 2 h following IFN-γ stimulation, despite equivalent quantities of mRNA, suggesting more efficient translation. This was significantly more pronounced in BS with high disease activity and in those with ocular and neurological clinical manifestations. The imbalance between CXCL10 protein and mRNA expression was not observed in either RA or SLE patients, and was not seen with other chemokines studied (CXCL9, CXCL11 and CCL2). Furthermore, BS monocytes treated with an alternative stimulant (LPS) did not show abnormal tumour necrosis factor (TNF)-α release. Sucrose density gradients to segregate monocyte CXCL10 mRNA into free RNA or polysome-associated RNA showed equal proportions in BS and HC samples, suggesting that the difference between BS and HC may be due to reduced negative control of CXCL10 translation in BS at a post-initiation level. We conclude that BS monocytes have dysfunctional post-transcriptional regulation of CXCL10 mRNA, resulting in over-expression of CXCL10 protein upon IFN-γ stimulation. As CXCL10 is a chemokine that recruits mononuclear cells, this abnormality may contribute to the exaggerated inflammatory responses that characterizes BS.
© 2015 British Society for Immunology.

Entities:  

Keywords:  Behçet's syndrome; chemokines; cytokines

Mesh:

Substances:

Year:  2015        PMID: 25982097      PMCID: PMC4557378          DOI: 10.1111/cei.12655

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker
Journal:  Ann Rheum Dis       Date:  2010-09       Impact factor: 19.103

Review 2.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

3.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

Review 4.  CXCR3 ligands in disease and therapy.

Authors:  Katrien Van Raemdonck; Philippe E Van den Steen; Sandra Liekens; Jo Van Damme; Sofie Struyf
Journal:  Cytokine Growth Factor Rev       Date:  2014-11-22       Impact factor: 7.638

5.  Characterization of the divergent wound-healing responses occurring in the pathergy reaction and normal healthy volunteers.

Authors:  Melike Melikoglu; Serpil Uysal; James G Krueger; Gilla Kaplan; Feride Gogus; Hasan Yazici; Stephen Oliver
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

6.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

7.  Mycobacterium tuberculosis increases IP-10 and MIG protein despite inhibition of IP-10 and MIG transcription.

Authors:  Xiyuan Bai; Kathryn Chmura; Alida R Ovrutsky; Russell P Bowler; Robert I Scheinman; Rebecca E Oberley-Deegan; Haiying Liu; Shaobin Shang; Diane Ordway; Edward D Chan
Journal:  Tuberculosis (Edinb)       Date:  2010-12-16       Impact factor: 3.131

8.  CXC chemokine expression profiles in aqueous humor of patients with different clinical entities of endogenous uveitis.

Authors:  Ahmed M Abu El-Asrar; Saleh S Al-Obeidan; Dustan Kangave; Karel Geboes; Ghislain Opdenakker; Jo Van Damme; Sofie Struyf
Journal:  Immunobiology       Date:  2011-04-07       Impact factor: 3.144

9.  The nuclear RNase III Drosha initiates microRNA processing.

Authors:  Yoontae Lee; Chiyoung Ahn; Jinju Han; Hyounjeong Choi; Jaekwang Kim; Jeongbin Yim; Junho Lee; Patrick Provost; Olof Rådmark; Sunyoung Kim; V Narry Kim
Journal:  Nature       Date:  2003-09-25       Impact factor: 49.962

Review 10.  Differential diagnosis and management of Behçet syndrome.

Authors:  Nicola L Ambrose; Dorian O Haskard
Journal:  Nat Rev Rheumatol       Date:  2012-09-25       Impact factor: 20.543

View more
  6 in total

1.  Longitudinal IP-10 Serum Levels Are Associated with the Course of Disease Activity and Remission in Patients with Rheumatoid Arthritis.

Authors:  Anouk van Hooij; Debbie M Boeters; Elisa M Tjon Kon Fat; Susan J F van den Eeden; Paul L A M Corstjens; Annette H M van der Helm-van Mil; Annemieke Geluk
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

Review 2.  The CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the Heart.

Authors:  Raffaele Altara; Ziad Mallat; George W Booz; Fouad A Zouein
Journal:  J Immunol Res       Date:  2016-10-03       Impact factor: 4.818

Review 3.  Knitting the Threads of Silk through Time: Behçet's Disease-Past, Present, and Future.

Authors:  Fahd Adeeb; Austin G Stack; Alexander D Fraser
Journal:  Int J Rheumatol       Date:  2017-09-10

4.  Anti-tubulin-alpha-1c antibody as a marker of value in Behçet syndrome.

Authors:  Mariam Maged Amin; Osama M Abdel Latif
Journal:  Clin Rheumatol       Date:  2022-02-07       Impact factor: 3.650

Review 5.  The Potential Role of Trained Immunity in Autoimmune and Autoinflammatory Disorders.

Authors:  Rob J W Arts; Leo A B Joosten; Mihai G Netea
Journal:  Front Immunol       Date:  2018-02-20       Impact factor: 7.561

6.  Circulating immune complexome analysis identified anti-tubulin-α-1c as an inflammation associated autoantibody with promising diagnostic value for Behcet's Disease.

Authors:  Yongjing Cheng; Xiaozhen Zhao; Yuling Chen; Yuhui Li; Rulin Jia; Lei Zhu; Cibo Huang; Xiaolin Sun; Haiteng Deng; Zhanguo Li
Journal:  PLoS One       Date:  2018-06-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.